Drug intelligence / Profile preview

D013

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

D013 is a drug developed by Chong Kun Dang Pharmaceutical. It is frequently studied in combination with D326 and D337, particularly in clinical trials evaluating pharmacokinetics and tolerability in healthy adult volunteers. D013 is also being investigated in Phase 3 clinical trials for its efficacy and safety as part of a combination therapy for the treatment of hypertension and dyslipidemia. The specific mechanism of action for D013 has not been disclosed in the provided context.

Beyond the preview

Go deeper on D013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D013.

Explore the full profile